Efficacy and Safety of CMA-676 in Patients With Acute Myelogenous Leukemia in First Relapse

Publication
Article
OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

CMA-676 (gemtuzumab zogamicin) is an antibody-targeted chemotherapeutic agent consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent cytotoxic

CMA-676 (gemtuzumab zogamicin) is an antibody-targeted chemotherapeutic agent consisting of a humanized anti-CD33 antibody linked to calicheamicin, a potent cytotoxic agent. This agent was designed to effectively deliver cytotoxic chemotherapy to acute myelogenous leukemia (AML) cells, while limiting nonhematopoietic toxicity.

In a phase II trial, CMA-676 was administered intravenously (IV) at a dose of 9 mg/m² every 2 weeks for two doses. Eligible patients had AML in first relapse following an initial remission of at least 6 months; those with secondary AML or preceding myelodysplastic syndromes were excluded.

A total of 59 patients entered the study prior to December 31, 1998. Median age was 53 years (range, 22 to 81 years). Of the 59 patients, 20 (34%) achieved a remission (characterized by < 5% blasts in the marrow, 1,500/µL neutrophils, and platelet transfusion independence prior to any additional post-remission therapy).

Median survival for all patients was 161 days, while that of patients achieving remission was not reached by the data cutoff date of March 15, 1999. Of the 20 patients who achieved remission, 12 remained relapse free, with a median follow-up of 238 days (range, 21 to 608 days).

Post-remission therapy was administered to 15 of the 20 patients (bone marrow transplantation [BMT] in 12 patients, chemotherapy in 3). Of the 15 patients, 1 died during a complete response (CR) due to transplant complications and 1 relapsed following allogeneic BMT. Two patients experienced a relapse following autologous BMT, with 1 patient expiring from progressive AML and 1 patient relapsing after receiving chemotherapy. Of the 5 patients who did not receive post-remission therapy, 3 relapsed and 2 remain leukemia free 4.5 and 3.5 months, respectively, after the first dose of CMA-676.

Overall, CMA-676 was well tolerated, as indicated by hospitalization for £ 1 week for 15 patients during treatment (ending 28 days after the last dose of CMA-676; excluding patients who expired during the same period). Severe (National Cancer Institute [NCI] grade 3-4) mucositis was not observed with CMA-676 treatment.

Adverse events following CMA-676 infusion frequently included self-limited fever, chills, and infrequently consisted of hypotension and shortness of breath. Almost all patients experienced grade 4 neutropenia and thrombocytopenia. Transient grade 3-4 increases in bilirubin and/or hepatic transaminases occurred in 9 patients. Individual patients experienced severe bone pain, intussusception, diabetes insipidus, seizures, exacerbation of disseminated intravascular coagulation, and intracerebral bleeding.

CONCLUSION: Antibody-targeted chemotherapy of AML cells via administration of CMA-676 as a single agent is associated with an acceptable safety profile while achieving

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin&#146;s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content